Pfizer Inc's pain reliever Celebrex should stay on the US market, despite risks of potential heart damage, a US advisory panel ruled on Friday. All but one panel member voted that the possible benefits from Celebrex outweigh the chances of cardiovascular problems.

Copyright Reuters, 2005